Marginal prescription equivalent to the isocenter prescription in lung stereotactic body radiotherapy: preliminary study for Japan Clinical Oncology Group trial (JCOG1408)

about

Marginal prescription equivalent to the isocenter prescription in lung stereotactic body radiotherapy: preliminary study for Japan Clinical Oncology Group trial (JCOG1408)

Item

http://www.wikidata.org/entity/Q37659318

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 19 October 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Marginal prescription equivale ...... ncology Group trial (JCOG1408)

@en

Marginal prescription equivale ...... Clinical Oncology Group trial

@nl

type

Item

label

Marginal prescription equivale ...... ncology Group trial (JCOG1408)

@en

Marginal prescription equivale ...... Clinical Oncology Group trial

@nl

prefLabel

Marginal prescription equivale ...... ncology Group trial (JCOG1408)

@en

Marginal prescription equivale ...... Clinical Oncology Group trial

@nl

P1476

Marginal prescription equivale ...... ncology Group trial (JCOG1408)

@en

P2093

Akito Saito

http://www.w3.org/2001/XMLSchema#string

Daisuke Kawahara

http://www.w3.org/2001/XMLSchema#string

Takeo Nakashima

http://www.w3.org/2001/XMLSchema#string

Teiji Nishio

http://www.w3.org/2001/XMLSchema#string

Tomoki Kimura

http://www.w3.org/2001/XMLSchema#string

Yasushi Nagata

http://www.w3.org/2001/XMLSchema#string

Yoshimi Ohno

http://www.w3.org/2001/XMLSchema#string

Yuji Murakami

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical introduction of Monte Carlo treatment planning: a different prescription dose for non-small cell lung cancer according to tumor location and size.

Dosimetric verification using monte carlo calculations for tissue heterogeneity-corrected conformal treatment plans following RTOG 0813 dosimetric criteria for lung cancer stereotactic body radiotherapy.

Conformity index: a review.

Differences in the dose-volume metrics with heterogeneity correction status and its influence on local control in stereotactic body radiation therapy for lung cancer.

Correlation between target volume and electron transport effects affecting heterogeneity corrections in stereotactic body radiotherapy for lung cancer.

Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study.

Prospective Trial of Stereotactic Body Radiation Therapy for Both Operable and Inoperable T1N0M0 Non-Small Cell Lung Cancer: Japan Clinical Oncology Group Study JCOG0403.

Phase I study of stereotactic body radiation therapy for peripheral T2N0M0 non-small cell lung cancer with PTV<100 cc using a continual reassessment method (JCOG0702).

Developing and evaluating stereotactic lung RT trials: what we should know about the influence of inhomogeneity corrections on dose.

Evaluation of heterogeneity dose distributions for Stereotactic Radiotherapy (SRT): comparison of commercially available Monte Carlo dose calculation with other algorithms.

P304

149-154

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JRR/RRW096

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Shuichi Ozawa

P577

2016-10-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28115532

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy

P932

5321195

http://www.w3.org/2001/XMLSchema#string